Bajaj Finserv Healthcare Fund - Growth - Regular Plan

Other Plans and Options
  • 0.31 %Nav, as on 10-06-2025

  • Previous Nav

  • Net Change on 10-06-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
BSE Health Care - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 14.47 24.39 21.58 1.80 8,352.16
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option Jul 13, 2018 23.40 28.50 24.95 1.91 5,507.52
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 21.33 28.00 23.82 1.94 3,689.28
Tata India Pharma & Healthcare Fund-Regular Plan-Growth Dec 28, 2015 14.69 23.79 21.04 2.15 1,231.67
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 21.43 25.31 21.53 2.25 1,062.19

Fund Holdings as on 31-May-2025

  • Divi's Laboratories Limited

  • Sun Pharmaceutical Industries Limited

  • Cipla Limited

  • Apollo Hospitals Enterprise Limited

  • Net Receivables / (Payables)

  • Dr. Reddy's Laboratories Limited

  • Piramal Pharma Limited

  • Biocon Limited

  • Emcure Pharmaceuticals Limited

  • Glenmark Pharmaceuticals Limited

  • Neuland Laboratories Limited

  • Syngene International Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Torrent Pharmaceuticals Limited

  • Abbott India Limited

  • Pfizer Limited

  • IPCA Laboratories Limited

  • Sanofi Consumer Healthcare India Limited

  • Rainbow Childrens Medicare Limited

  • Zydus Wellness Limited

  • Dr. Lal Path Labs Limited

  • Vijaya Diagnostic Centre Limited

  • Fortis Healthcare Limited

  • Hindustan Unilever Limited

  • Shaily Engineering Plastics Limited

  • Alkem Laboratories Limited

  • Orchid Pharma Limited

  • Emami Limited

  • Medi Assist Healthcare Services Limited

  • MedPlus Health Services Limited

  • Jubilant Pharmova Limited

  • Alembic Pharmaceuticals Limited

  • Max Healthcare Institute Limited

  • Lupin Limited

  • Marico Limited

  • AstraZeneca Pharma India Limited

  • Mankind Pharma Limited

  • Aurobindo Pharma Limited

  • Nestle India Limited

  • Neogen Chemicals Limited

  • PB Fintech Limited

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Business Support

  • Consumer Food

  • Household & Personal Products

  • Plastic Products

  • Chemicals

  • Fintech

View More

Fund Manager

  • Cash

  • Equity

View More

About Bajaj Finserv Healthcare Fund

Scheme Analysis

Bajaj Finserv Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Bajaj Finserv Mutual Fund. It was launched on 27-Dec-2024 and currently has an AUM of ₹321.02 crore. Bajaj Finserv Healthcare Fund is benchmarked against BSE Health Care - TRI as primary index.

The NAV of Bajaj Finserv Healthcare Fund ended up ₹0.03(0.31%)yesterday to ₹9.599.

Among its top 3 holdings the fund has exposure to Divi's Laboratories Limited, and

The Bajaj Finserv Healthcare Fund is managed by Nimesh Chandan and Siddharth Chaudhary.

Fund House Contact

S. No. 208/1B, Lohagaon Viman Nagar Pune - 411014

1800-309-3900
service@bajajamc.com
020-67672550